Wg report backs new tb vaccines tb hiv
This presentation is the property of its rightful owner.
Sponsored Links
1 / 7

WG report backs: New TB Vaccines & TB/HIV PowerPoint PPT Presentation


  • 55 Views
  • Uploaded on
  • Presentation posted in: General

WG report backs: New TB Vaccines & TB/HIV. INAT Meeting November 12, 2010 Berlin. Goal and strategies for New TB Vaccines. Safe and effective in preventing TB - including M/XDR- in children, adolescents and adults, including people with HIV Types of Vaccines Preexposure

Download Presentation

WG report backs: New TB Vaccines & TB/HIV

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Wg report backs new tb vaccines tb hiv

WG report backs:New TB Vaccines & TB/HIV

INAT Meeting

November 12, 2010

Berlin


Goal and strategies for new tb vaccines

Goal and strategies forNew TB Vaccines

  • Safe and effective in preventing TB - including M/XDR- in children, adolescents and adults, including people with HIV

  • Types of Vaccines

    • Preexposure

    • Postexposure (Current BCG vaccine strategy)

    • Immunotherapy

  • Prime-Boost Strategy

    • Boost BCG or a recombinant BCG (rBCG) with a second, different vaccine designed to extend and enhance immune protection

    • Replace BCG with a recombinant BCG (rBCG) or attenuated live M.tb vaccine as the prime


Tb vaccine pipeline

TB Vaccine Pipeline

As of November 2009

Preclinical

Phase I

Phase II

Phase IIb

Phase III

AERAS-422Aeras

Mtb [∆lysA ∆panCD ∆secA2]Albert Einstein College of Medicine

MTBVAC01 [∆phoP, ∆fad D26]University of Zaragoza, Institute Pasteur, TuBerculosis Vaccine Initiative (TBVI)

HBHAInstitute Pasteur of Lille, INSERM, TBVI

Hybrid 56Statens Serum Institute (SSI), Aeras, Intercell, TBVI

HG85 A/BShanghai H&G Biotech

Hybrid-I+IC31SSI, TBVI, Intercell

M72GSK, Aeras

MVA85A/AERAS-485Oxford-Emergent Tuberculosis Consortium (OETC), Aeras

AERAS-402/ Crucell Ad35Crucell, Aeras

M vaccae*Immodulon, NIH

VPM 1002Max Planck, Vakzine Projekt Mgmt, TBVI

rBCG30*UCLA, NIH, NIAID, Aeras

AdAg85AMcMaster University

Hybrid-I+CAF01SSI

Hyvac 4/ AERAS-404SSI, Sanofi-Pasteur, Aeras, Intercell

RUTIArchivel Farma

M smegmatis*

Prime

Boost

Post-infection

Immunotherapy

Preclinical vaccine candidates are not yet in clinical trials, but have been manufactured under Good Manufacturing Practice (GMP) for clinical use and have undergone some preclinical testing that meets regulatory standards.

*indicates candidates that have been in clinical trials in the past, but are not currently being tested in clinical trials

Source: Tuberculosis Vaccine Candidates – 2009; Stop TB Partnership Working Group on New TB Vaccines


Facilitating access to new tb vaccines

Facilitating access to New TB Vaccines

Include new TB vaccines in EPI programs and extend the system to adolescent/adult vaccination

Consider appropriate and innovative licensure procedures to accelerate access to market

Strengthen health systems and identify innovative approaches to allow for mass vaccinations

Find the “reasonable” balance between affordability, direct and indirect return on investment, societal benefits and sustainable production


Role for inat

Role for INAT?

  • Can INAT play a role in clarifying the regulatory pathway?

  • Help to clarify WHO mechanism (eg. STAG’s role in SAGE) and accelerate pre-qualification (can this process be done in conjunction with phase III studies)

  • Assist in identifying what information is needed and by whom (eg. MOH, EPI and/or NTP) to make decisions about uptake of vaccines on country level


Current priorities of tb hiv wg

Current priorities of TB/HIV WG

  • 3 I’s - IPT/ICF Guidelines

  • Global Consultation on the implementation considerations for scale-up of Xpert MTB/RIF

  • TB/HIV Collaborative Policy revision

  • Focus on delivery of decentralized HIV services (eg. ART) in TB settings

  • Ensuring linkages between diagnostic and care

  • Systematize and regulate use of GeneXpert at PEPFAR sites


Role of inat

Role of INAT?

  • Influence NACP and HIV service providers

  • Need guidance from INAT on the role they can play for implementation WGs


  • Login